A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice - PubMed (original) (raw)
. 2002 Jun;160(6):2295-307.
doi: 10.1016/S0002-9440(10)61177-7.
Susan Guillet, Elizabeth Tomlinson, Kenneth Hillan, Barbara Wright, Gretchen D Frantz, Thinh A Pham, Lisa Dillard-Telm, Siao Ping Tsai, Jean-Philippe Stephan, Jeremy Stinson, Timothy Stewart, Dorothy M French
Affiliations
- PMID: 12057932
- PMCID: PMC1850847
- DOI: 10.1016/S0002-9440(10)61177-7
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice
Katrina Nicholes et al. Am J Pathol. 2002 Jun.
Abstract
Most mouse models of hepatocellular carcinoma have expressed growth factors and oncogenes under the control of a liver-specific promoter. In contrast, we describe here the formation of liver tumors in transgenic mice overexpressing human fibroblast growth factor 19 (FGF19) in skeletal muscle. FGF19 transgenic mice had elevated hepatic alpha-fetoprotein mRNA as early as 2 months of age, and hepatocellular carcinomas were evident by 10 months of age. Increased proliferation of pericentral hepatocytes was demonstrated by 5-bromo-2'-deoxyuridine incorporation in the FGF19 transgenic mice before tumor formation and in nontransgenic mice injected with recombinant FGF19 protein. Areas of small cell dysplasia were initially evident pericentrally, and dysplastic/neoplastic foci throughout the hepatic lobule were glutamine synthetase-positive, suggestive of a pericentral origin. Consistent with chronic activation of the Wingless/Wnt pathway, 44% of the hepatocellular tumors from FGF19 transgenic mice had nuclear staining for beta-catenin. Sequencing of the tumor DNA encoding beta-catenin revealed point mutations that resulted in amino acid substitutions. These findings suggest a previously unknown role for FGF19 in hepatocellular carcinomas.
Figures
Figure 1.
Preneoplastic hepatocellular changes in FGF19 transgenic mice. As early as 14 weeks of age pericentral hepatocytes formed a dense cluster around the central veins (arrows) with polarization of nuclei of the innermost hepatocytes away from the vessel lumen in FGF19 transgenics (A) that was not present in liver from nontransgenic littermate mice (B). Pericentral small dysplastic hepatocytes (C) were the predominant type of hepatocellular dysplasia although foci of large dysplastic hepatocytes (D) were occasionally noted. Arrows delineate areas of altered hepatocellular foci (shown at higher magnification in the insets). Original magnifications: ×100 (A and B); ×400 (C and D). Inset original magnifications: ×400 (A and B); ×600 (C and D).
Figure 2.
Hepatocellular neoplasia in FGF19 transgenic mice. A: Multiple, large, raised tumors protrude from the hepatic surface of the liver from a 10-month-old FGF19 transgenic mouse (arrows). B: Histologically, neoplastic cells invade and replace normal hepatic architecture and are arranged in solid sheets or cords. Arrows mark the border of the tumor and adjacent normal liver. C: Pleomorphism of neoplastic hepatocytes and atypical mitotic figures (arrows). Original magnifications: ×40 (B); ×400 (C).
Figure 3.
FGFR4 expression in murine liver. Bright-field (A) and dark-field (B) illumination of in situ hybridization with a murine FGFR4 riboprobe showing expression in perivenular and random hepatocytes. C and D: Higher magnification of bright-field demonstrating silver grains over random small hepatocytes. Original magnifications: ×100 (A and B); ×400 (C and D).
Figure 4.
Increased proliferation of pericentral hepatocytes in FGF19 transgenics. Immunostaining for BrdU after a 5-day infusion by osmotic minipump of liver from a wild-type (A) and a FGF19 transgenic mouse (B). Morphometric analysis of BrdU-immunostained sections from FGF19 transgenics compared to wild-type mice: 2 to 4 months (C), 7 to 9 months (D), and FGF19-injected mice (E). The labeling index denotes the number of BrdU-positive hepatocytes divided by the total number of cells counted and indicated as a percentage. *, P < 0.05. Original magnifications: ×200 (A and B); ×600 (inset in B).
Figure 5.
Glutamine synthetase immunoreactivity of dysplastic and neoplastic hepatocytes from FGF19 transgenics. A: Neoplastic cells are strongly glutamine synthetase-positive. B: Liver from a wild-type mouse showing normal perivenular glutamine synthetase immunostaining. C: Dysplastic hepatocytes are strongly glutamine synthetase-positive. D: Normal glutamine synthetase immunoreactivity of perivenular hepatocytes. Original magnifications: ×40 (A and B); ×400 (C and D).
Figure 6.
Expression of AFP by neoplastic and dysplastic hepatocytes. Increased expression of AFP mRNA in FGF19 transgenic liver compared to wild-type liver at 2 to 4 months of age (A) and 7 to 9 months of age (B). *, P < 0.05. Bright-field (C) and dark-field (D) illumination of in situ hybridization with AFP riboprobe showing expression of AFP by pericentral dysplastic hepatocytes (arrows). Bright-field (E) and dark-field (F) illumination of in situ hybridization with AFP riboprobe showing expression of AFP by neoplastic hepatocytes (arrows). Original magnifications, ×100.
Figure 7.
β-Catenin immunoreactivity of neoplastic hepatocytes from FGF19 transgenics. A: Strong nuclear staining of neoplastic cells compared with surrounding liver. Arrows mark the border of the tumor and adjacent normal liver. B: Neoplastic hepatocytes with nuclear immunoreactivity for β-catenin. C: Amino acid sequence alignment of the N-terminal region of β-catenin from wild-type (top) and mutant clones with amino acid substitutions (bold) in and adjacent to the GSK-3B phosphorylation domain (red). D: Sequencing data for DNA from normal liver and HCC with nucleotide substitutions at codon 34 (shaded). Original magnifications: ×200 (A); ×400 (B).
Similar articles
- Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade.
Calvisi DF, Factor VM, Loi R, Thorgeirsson SS. Calvisi DF, et al. Cancer Res. 2001 Mar 1;61(5):2085-91. Cancer Res. 2001. PMID: 11280770 - Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis.
Hollmann CA, Kittrell FS, Medina D, Butel JS. Hollmann CA, et al. Oncogene. 2001 Nov 15;20(52):7645-57. doi: 10.1038/sj.onc.1204980. Oncogene. 2001. PMID: 11753642 - Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
Desnoyers LR, Pai R, Ferrando RE, Hötzel K, Le T, Ross J, Carano R, D'Souza A, Qing J, Mohtashemi I, Ashkenazi A, French DM. Desnoyers LR, et al. Oncogene. 2008 Jan 3;27(1):85-97. doi: 10.1038/sj.onc.1210623. Epub 2007 Jun 25. Oncogene. 2008. PMID: 17599042 - Overview of the molecular biology of hepatocellular neoplasms and hepatoblastomas of the mouse liver.
Kim Y, Sills RC, Houle CD. Kim Y, et al. Toxicol Pathol. 2005;33(1):175-80. doi: 10.1080/01926230590522130. Toxicol Pathol. 2005. PMID: 15805069 Review. - [beta-catenin].
Ogawa K, Yaginuma Y. Ogawa K, et al. Nihon Rinsho. 2001 Oct;59 Suppl 6:161-6. Nihon Rinsho. 2001. PMID: 11761935 Review. Japanese. No abstract available.
Cited by
- Understanding Gene Involvement in Hepatocellular Carcinoma: Implications for Gene Therapy and Personalized Medicine.
Younis MA, Harashima H. Younis MA, et al. Pharmgenomics Pers Med. 2024 May 7;17:193-213. doi: 10.2147/PGPM.S431346. eCollection 2024. Pharmgenomics Pers Med. 2024. PMID: 38737776 Free PMC article. Review. - FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis.
Ursic-Bedoya J, Desandré G, Chavey C, Marie P, Polizzi A, Rivière B, Guillou H, Assenat E, Hibner U, Gregoire D. Ursic-Bedoya J, et al. EMBO Mol Med. 2024 Feb;16(2):238-250. doi: 10.1038/s44321-023-00021-x. Epub 2024 Jan 16. EMBO Mol Med. 2024. PMID: 38228803 Free PMC article. - MASLD treatment-a shift in the paradigm is imminent.
Machado MV. Machado MV. Front Med (Lausanne). 2023 Dec 11;10:1316284. doi: 10.3389/fmed.2023.1316284. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38146424 Free PMC article. Review. - Liver organoid culture methods.
Hu Y, Hu X, Luo J, Huang J, Sun Y, Li H, Qiao Y, Wu H, Li J, Zhou L, Zheng S. Hu Y, et al. Cell Biosci. 2023 Nov 1;13(1):197. doi: 10.1186/s13578-023-01136-x. Cell Biosci. 2023. PMID: 37915043 Free PMC article. Review. - Targeting FGFR Pathways in Gastrointestinal Cancers: New Frontiers of Treatment.
Ratti M, Orlandi E, Hahne JC, Vecchia S, Citterio C, Anselmi E, Toscani I, Ghidini M. Ratti M, et al. Biomedicines. 2023 Sep 27;11(10):2650. doi: 10.3390/biomedicines11102650. Biomedicines. 2023. PMID: 37893023 Free PMC article. Review.
References
- Marsh SK, Bansal GS, Zammit C, Barnard R, Coope R, Roberts-Clarke D, Gomm JJ, Coombes RC, Johnston CL: Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene 1999, 18:1053-1060 - PubMed
- Mattila MM, Ruohola JK, Valve EM, Tasanen MJ, Seppanen JA, Harkonen PL: FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells. Oncogene 2001, 20:2791-2804 - PubMed
- Ruohola JK, Viitanen TP, Valve EM, Seppanen JA, Loponen NT, Keskitalo JJ, Lakkakorpi PT, Harkonen PL: Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res 2001, 61:4229-4237 - PubMed
- Valve EM, Nevalainen MT, Nurmi MJ, Laato MK, Martikainen PM, Harkonen PL: Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab Invest 2001, 81:815-826 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous